Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1Phase 1/2 1

Status

Completed 16Terminated 5Recruiting 5Active not recruiting 4Withdrawn 3Unknown 1Not yet recruiting 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Other hematologic neoplasm 1Dermatologic 1CNS 1

Conditions

Carcinoma, Hepatocellular 2Uveal Melanoma 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Neoplasms 1Leukemia, Myeloid, Acute 1Glioma 1Colorectal Neoplasms 1Carcinoma 1Advanced Solid Cancers 1

Interventions

Cyclophosphamide 390Carboplatin 344Gemcitabine 332pembrolizumab 329Cisplatin 328Paclitaxel 297Radiotherapy 296Docetaxel 286Bevacizumab 253Rituximab 234Capecitabine 223Nivolumab 220Dexamethasone 206Fluorouracil 190fludarabine 177Oxaliplatin 177Pemetrexed 153Doxorubicin 153Irinotecan 148Leucovorin 144Etoposide 144Cytarabine 133Cetuximab 129Bortezomib 129fludarabine phosphate 128Lenalidomide 126Erlotinib Hydrochloride 120Filgrastim 119Temozolomide 113Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Terminated × ADI PEG20 × Clear all
NCT01266018 2022-10-25

Study of ADI-PEG 20 in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer

Ludwig Institute for Cancer Research

Phase 2 Terminated
22 enrolled 14 charts
Thoracic

Small Cell Lung Carcinoma

NCT03254732 2022-04-27

Study ADI-PEG 20 Plus Pembrolizumab in Advanced Solid Cancers

Polaris Group

Phase 1 Terminated
33 enrolled

Advanced Solid Cancers

NCT02102022 2022-04-25

Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma

Polaris Group

Phase 1/2 Terminated
140 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT02029690 2020-09-25

TRAP

Polaris Group

Phase 1 Terminated
85 enrolled
CNSDermatologicGastrointestinal

Uveal Melanoma, Carcinoma, Glioma, Carcinoma, Hepatocellular

NCT02875093 2020-03-05

Ph 1 Study of ADI-PEG 20 Plus Low Dose Cytarabine in Older Patients With AML

Polaris Group

Phase 1 Terminated
23 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡